The proposed IPO comes months after BioAge raised $170 million in a funding round led by life sciences investment firm Sofinnova Investments. The company lost $26.6 million in the first half of ...
BioAge Labs filed confidentially on May 31, 2024. Goldman Sachs, Morgan Stanley, Jefferies, and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.
The company's lead drug Azelaprag has been well-tolerated in 265 individuals across eight Phase 1 trials. The STRIDES clinical trial will assess azelaprag with Eli Lilly's Zepbound, with topline ...
BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015 ...
Some results have been hidden because they may be inaccessible to you